Physician profile
Tamara Erlikh
NPI 1518900471
$5,581.22
in general payments reported to CMS, 2019-2025
30 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $277 · 2021: $772 · 2022: $759 · 2023: $1,036 · 2024: $1,067 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,719.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $933.64 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $495.72 | 2019-2025 | |
| Abbvie INC. | $471.54 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $466.86 | 2020-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.85 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $337.22 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Novo Nordisk INC | $291.46 | 2019-2022 | |
| Glaxosmithkline, LLC. | $283.46 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Intra-Sana Laboratories | $239.42 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Exact Sciences Corporation | $236.12 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $148.94 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $144.86 | 2019-2025 | Veozah |
| Lilly USA, LLC | $139.78 | 2019-2024 | Mounjaro |
| Daiichi Sankyo INC. | $136.56 | 2019-2023 | Injectafer |
| Allergan, INC. | $108.82 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $94.92 | 2024-2025 | Rexulti, Vyepti |
| Dexcom, INC. | $77.64 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $72.32 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $63.88 | 2024-2025 | Vowst |
| Janssen Pharmaceuticals, INC | $60.13 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $54.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.35 | 2022-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $42.95 | 2022-2025 | |
| Shield Therapeutics INC | $39.46 | 2024 | |
| Ironwood Pharmaceuticals, INC | $31.91 | 2021 | |
| Aurinia Pharma U.S., INC. | $24.40 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.29 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.82 | 2024 | Voquezna |
| Amarin Pharma, INC. | $14.57 | 2020 | |
| Sanofi Pasteur INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Erlikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.